Activity of tedizolid (TR-700) against well-characterized methicillin-resistant staphylococcus aureus strains of diverse epidemiological origins

Kenneth S. Thomson, Richard V. Goering

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The in vitro activities of tedizolid and 10 antistaphylococcal agents were compared against 111 methicillin-resistant Staphylococcus aureus (MRSA) strains from 14 epidemiologically characterized groups. Tedizolid, tigecycline, and daptomycin were the most potent agents, with tedizolid 4-fold more potent than linezolid. Tedizolid, linezolid, and vancomycin were unaffected by epidemiological types. Tigecycline and daptomycin had reduced potency against ST80-MRSA-IV and ST239-MRSA-III, respectively. Overall, tedizolid was highly potent against all MRSA strain types, including those resistant to other classes of drugs.

Original languageEnglish
Pages (from-to)2892-2895
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Linezolid
Methicillin-Resistant Staphylococcus aureus
Daptomycin
Vancomycin
torezolid
Pharmaceutical Preparations
tigecycline

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

@article{417ba603e01146b9a357b10afaa63646,
title = "Activity of tedizolid (TR-700) against well-characterized methicillin-resistant staphylococcus aureus strains of diverse epidemiological origins",
abstract = "The in vitro activities of tedizolid and 10 antistaphylococcal agents were compared against 111 methicillin-resistant Staphylococcus aureus (MRSA) strains from 14 epidemiologically characterized groups. Tedizolid, tigecycline, and daptomycin were the most potent agents, with tedizolid 4-fold more potent than linezolid. Tedizolid, linezolid, and vancomycin were unaffected by epidemiological types. Tigecycline and daptomycin had reduced potency against ST80-MRSA-IV and ST239-MRSA-III, respectively. Overall, tedizolid was highly potent against all MRSA strain types, including those resistant to other classes of drugs.",
author = "Thomson, {Kenneth S.} and Goering, {Richard V.}",
year = "2013",
month = "6",
doi = "10.1128/AAC.00274-13",
language = "English",
volume = "57",
pages = "2892--2895",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Activity of tedizolid (TR-700) against well-characterized methicillin-resistant staphylococcus aureus strains of diverse epidemiological origins

AU - Thomson, Kenneth S.

AU - Goering, Richard V.

PY - 2013/6

Y1 - 2013/6

N2 - The in vitro activities of tedizolid and 10 antistaphylococcal agents were compared against 111 methicillin-resistant Staphylococcus aureus (MRSA) strains from 14 epidemiologically characterized groups. Tedizolid, tigecycline, and daptomycin were the most potent agents, with tedizolid 4-fold more potent than linezolid. Tedizolid, linezolid, and vancomycin were unaffected by epidemiological types. Tigecycline and daptomycin had reduced potency against ST80-MRSA-IV and ST239-MRSA-III, respectively. Overall, tedizolid was highly potent against all MRSA strain types, including those resistant to other classes of drugs.

AB - The in vitro activities of tedizolid and 10 antistaphylococcal agents were compared against 111 methicillin-resistant Staphylococcus aureus (MRSA) strains from 14 epidemiologically characterized groups. Tedizolid, tigecycline, and daptomycin were the most potent agents, with tedizolid 4-fold more potent than linezolid. Tedizolid, linezolid, and vancomycin were unaffected by epidemiological types. Tigecycline and daptomycin had reduced potency against ST80-MRSA-IV and ST239-MRSA-III, respectively. Overall, tedizolid was highly potent against all MRSA strain types, including those resistant to other classes of drugs.

UR - http://www.scopus.com/inward/record.url?scp=84877844310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877844310&partnerID=8YFLogxK

U2 - 10.1128/AAC.00274-13

DO - 10.1128/AAC.00274-13

M3 - Article

C2 - 23571550

AN - SCOPUS:84877844310

VL - 57

SP - 2892

EP - 2895

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -